Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Declines By 27.1%

Biofrontera Inc. (NASDAQ:BFRI) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 136,600 shares, a decline of 27.1% from the August 31st total of 187,300 shares. Based on an average daily volume of 223,500 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.6% of the company’s stock are sold short. Currently, 1.6% of the company’s stock are sold short. Based on an average daily volume of 223,500 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Biofrontera in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biofrontera currently has a consensus rating of “Hold” and an average target price of $2.75.

Biofrontera Price Performance

Shares of NASDAQ BFRI opened at $1.01 on Thursday. Biofrontera has a twelve month low of $0.54 and a twelve month high of $2.22. The company has a current ratio of 0.96, a quick ratio of 0.75 and a debt-to-equity ratio of 8.99. The company has a market capitalization of $10.24 million, a price-to-earnings ratio of -0.45 and a beta of 0.53. The business has a 50 day simple moving average of $0.93 and a 200-day simple moving average of $0.81.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). Biofrontera had a negative net margin of 42.34% and a negative return on equity of 1,104.09%. The firm had revenue of $9.03 million during the quarter, compared to the consensus estimate of $8.30 million. As a group, equities research analysts expect that Biofrontera will post -3.01 earnings per share for the current year.

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. grew its position in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the quarter. Biofrontera makes up approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th largest position. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 at the end of the most recent quarter. 10.08% of the stock is currently owned by institutional investors and hedge funds.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.